Compugen Ltd Quick Ratio (CGEN) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Compugen Ltd  (NASDAQ: CGEN)

Compugen Ltd's Quick Ratio

CGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Compugen Ltd's Cash & cash equivalent, this led to improvement in Compugen Ltd's Quick Ratio to 7.67, Quick Ratio remained below Compugen Ltd average.

Within Biotechnology & Pharmaceuticals industry 28 other companies have achieved higher Quick Ratio than Compugen Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 250 to 305.

Explain Quick Ratio?
How much Cash & cash equivalents CGEN´s has?
What are CGEN´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CGEN Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 14.19 % 11.86 % -12.54 % 11.86 % -26.08 %
Y / Y Cash & cash equivalent Change 41.05 % 41.05 % 2.04 % 41.05 % 102.26 %
Quick Ratio MRQ 7.67 6.61 5.31 6.61 6.21
CGEN's Total Ranking # 305 # 250 # # #
Seq. Current Liabilities Change -13.83 % 24.63 % -19.77 % 32.52 % -15.59 %
Seq. Cash & cash equivalent Change 0 % 55.14 % -35.54 % 41.05 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 29
Healthcare Sector # 145
Overall Market # 305


Quick Ratio Statistics
High Average Low
17.98 7.77 4.91
(Dec 31 2012)   (Dec 31 2017)




Financial Statements
Compugen Ltd's Current Liabilities $ 19 Millions Visit CGEN's Balance sheet
Compugen Ltd's Cash & cash equivalent $ 146 Millions Visit CGEN's Balance sheet
Source of CGEN's Sales Visit CGEN's Sales by Geography


Cumulative Compugen Ltd's Quick Ratio

CGEN's Quick Ratio for the trailling 12 Months

CGEN Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 5.9 % -4.54 % 4.75 % 35.72 % 52.15 %
Y / Y Cash & cash equivalent TTM Growth 32.11 % 39.72 % 42.57 % 45.84 % 40.97 %
Quick Ratio TTM 6.57 6.23 5.86 5.65 5.27
Total Ranking TTM # 2353 # 3302 # # #
Seq. Current Liabilities TTM Growth 3.01 % 3.07 % -3.23 % 3.06 % -7.15 %
Seq. Cash & cash equivalent TTM Growth 8.68 % 9.5 % 0.42 % 10.55 % 14.93 %

Quick ratio ranking by company, industry and sector >> Back to CGEN Financial Strength Comparisons >> Go to Compare CGEN Quick Ratio to its Competitors

On the trailing twelve months basis CGEN Cash & cash equivalent soared by 41.05 % in Q4 2025 year on year, faster than Current Liabilities, this led to increase in in Compugen Ltd's Quick Ratio to 6.57, Quick Ratio remained below CGEN average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 92 other companies have achieved higher Quick Ratio than Compugen Ltd. While Quick Ratio overall ranking has improved so far to 2353, from total ranking during the twelve months ending third quarter 2025 at 3302.

Explain Quick Ratio?
How much Cash & cash equivalents CGEN´s has?
What are CGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 93
Healthcare Sector # 590
Within the Market # 2353


trailing twelve months Quick Ratio Statistics
High Average Low
11.82 7.03 4.79
(Dec 31 2020)   0




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Protara Therapeutics Inc  20.72 $ 200.909  Millions$ 9.697  Millions
Leonabio Inc   18.50 $ 176.631  Millions$ 9.550  Millions
Hemab Therapeutics Holdings Inc   18.49 $ 185.485  Millions$ 10.030  Millions
Vor Biopharma Inc   18.29 $ 455.208  Millions$ 24.891  Millions
Kyverna Therapeutics Inc   18.26 $ 279.253  Millions$ 15.296  Millions
Kymera Therapeutics Inc   18.23 $ 848.276  Millions$ 46.531  Millions
Maze Therapeutics Inc   15.16 $ 341.917  Millions$ 22.556  Millions
Compass Therapeutics Inc   14.96 $ 208.906  Millions$ 13.968  Millions
Candel Therapeutics Inc   14.00 $ 119.731  Millions$ 8.552  Millions
In8bio Inc   13.95 $ 27.092  Millions$ 1.942  Millions
Genenta Science S p a   13.29 $ 31.527  Millions$ 2.372  Millions
Crispr Therapeutics Ag  13.25 $ 1,975.828  Millions$ 149.120  Millions
Tscan Therapeutics Inc   13.22 $ 152.406  Millions$ 11.528  Millions
Eikon Therapeutics Inc   13.15 $ 335.975  Millions$ 25.549  Millions
Precision Biosciences Inc  12.97 $ 115.585  Millions$ 8.913  Millions
Beam Therapeutics Inc   12.85 $ 1,245.210  Millions$ 96.935  Millions
Anavex Life Sciences Corp   12.60 $ 102.577  Millions$ 8.141  Millions
Vaxcyte Inc   12.49 $ 1,560.959  Millions$ 124.972  Millions
Kalaris Therapeutics Inc   12.15 $ 117.982  Millions$ 9.714  Millions
Imagenebio Inc   12.05 $ 135.349  Millions$ 11.234  Millions
Taysha Gene Therapies Inc   12.04 $ 319.767  Millions$ 26.552  Millions
Immunovant Inc   10.40 $ 713.971  Millions$ 68.677  Millions
Cullinan Therapeutics Inc   10.22 $ 377.896  Millions$ 36.961  Millions
X4 Pharmaceuticals Inc  9.82 $ 252.998  Millions$ 25.757  Millions
Molecular Partners Ag  9.44 $ 104.149  Millions$ 11.027  Millions
4d Molecular Therapeutics Inc   9.15 $ 402.655  Millions$ 43.985  Millions
Prokidney Corp   9.10 $ 270.017  Millions$ 29.671  Millions
Sab Biotherapeutics Inc   9.04 $ 96.592  Millions$ 10.681  Millions
Denali Therapeutics Inc   8.82 $ 867.879  Millions$ 98.351  Millions
Artiva Biotherapeutics Inc   8.25 $ 108.008  Millions$ 13.087  Millions

Date modified: 2026-07-07T15:05:19+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.